The global Circulating Tumor Cells market size was valued at US$ 2357 million in 2024 and is forecast to a readjusted size of USD 8297 million by 2031 with a CAGR of 19.9% during review period.
Circulating tumor cells are cancer cells that have detached from the tumor and are found at extremely low levels in the bloodstream. The value of capturing and counting CTCs is evolving as more research data is gathered about the utility of these markers in monitoring disease progression and potentially guiding personalized cancer therapy.
Global Circulating Tumor Cells main players are Menarini-Silicon Biosystems, Qiagen锛圓dnagen锛�, Clearbridge Biomedics, Celsee, Fluidigm. Global top five manufacturers hold a share over 30%.
This report is a detailed and comprehensive analysis for global Circulating Tumor Cells market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Circulating Tumor Cells market size and forecasts, in consumption value ($ Million), 2020-2031
Global Circulating Tumor Cells market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
Global Circulating Tumor Cells market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031
Global Circulating Tumor Cells market shares of main players, in revenue ($ Million), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Circulating Tumor Cells
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Circulating Tumor Cells market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Menarini-Silicon Biosystems, Qiagen (Adnagen), Advanced Cell Diagnostics, ApoCell, Epic Sciences, Greiner Bio-one GmbH, Cynvenio, SurExamBio-Tech, Fluxion Biosciences, Ikonisys, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
麻豆原创 segmentation
Circulating Tumor Cells market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segment by Type
CTC Enrichment
CTC Detection
CTC Analysis
麻豆原创 segment by Application
Breast Cancer
Prostate Cancer
Colorectal Cancer
Lung Cancer
Others
麻豆原创 segment by players, this report covers
Menarini-Silicon Biosystems
Qiagen (Adnagen)
Advanced Cell Diagnostics
ApoCell
Epic Sciences
Greiner Bio-one GmbH
Cynvenio
SurExamBio-Tech
Fluxion Biosciences
Ikonisys
Hangzhou Watson Biotech
Biocept
CytoTrack
Guangzhou Wondfo Biotech
Celsee
Clearbridge Biomedics
ANGLE plc
麻豆原创 segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Circulating Tumor Cells product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Circulating Tumor Cells, with revenue, gross margin, and global market share of Circulating Tumor Cells from 2020 to 2025.
Chapter 3, the Circulating Tumor Cells competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Circulating Tumor Cells market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Circulating Tumor Cells.
Chapter 13, to describe Circulating Tumor Cells research findings and conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.
1 麻豆原创 Overview
1.1 Product Overview and Scope
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 Classification of Circulating Tumor Cells by Type
1.3.1 Overview: Global Circulating Tumor Cells 麻豆原创 Size by Type: 2020 Versus 2024 Versus 2031
1.3.2 Global Circulating Tumor Cells Consumption Value 麻豆原创 Share by Type in 2024
1.3.3 CTC Enrichment
1.3.4 CTC Detection
1.3.5 CTC Analysis
1.4 Global Circulating Tumor Cells 麻豆原创 by Application
1.4.1 Overview: Global Circulating Tumor Cells 麻豆原创 Size by Application: 2020 Versus 2024 Versus 2031
1.4.2 Breast Cancer
1.4.3 Prostate Cancer
1.4.4 Colorectal Cancer
1.4.5 Lung Cancer
1.4.6 Others
1.5 Global Circulating Tumor Cells 麻豆原创 Size & Forecast
1.6 Global Circulating Tumor Cells 麻豆原创 Size and Forecast by Region
1.6.1 Global Circulating Tumor Cells 麻豆原创 Size by Region: 2020 VS 2024 VS 2031
1.6.2 Global Circulating Tumor Cells 麻豆原创 Size by Region, (2020-2031)
1.6.3 North America Circulating Tumor Cells 麻豆原创 Size and Prospect (2020-2031)
1.6.4 Europe Circulating Tumor Cells 麻豆原创 Size and Prospect (2020-2031)
1.6.5 Asia-Pacific Circulating Tumor Cells 麻豆原创 Size and Prospect (2020-2031)
1.6.6 South America Circulating Tumor Cells 麻豆原创 Size and Prospect (2020-2031)
1.6.7 Middle East & Africa Circulating Tumor Cells 麻豆原创 Size and Prospect (2020-2031)
2 Company Profiles
2.1 Menarini-Silicon Biosystems
2.1.1 Menarini-Silicon Biosystems Details
2.1.2 Menarini-Silicon Biosystems Major Business
2.1.3 Menarini-Silicon Biosystems Circulating Tumor Cells Product and Solutions
2.1.4 Menarini-Silicon Biosystems Circulating Tumor Cells Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.1.5 Menarini-Silicon Biosystems Recent Developments and Future Plans
2.2 Qiagen (Adnagen)
2.2.1 Qiagen (Adnagen) Details
2.2.2 Qiagen (Adnagen) Major Business
2.2.3 Qiagen (Adnagen) Circulating Tumor Cells Product and Solutions
2.2.4 Qiagen (Adnagen) Circulating Tumor Cells Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.2.5 Qiagen (Adnagen) Recent Developments and Future Plans
2.3 Advanced Cell Diagnostics
2.3.1 Advanced Cell Diagnostics Details
2.3.2 Advanced Cell Diagnostics Major Business
2.3.3 Advanced Cell Diagnostics Circulating Tumor Cells Product and Solutions
2.3.4 Advanced Cell Diagnostics Circulating Tumor Cells Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.3.5 Advanced Cell Diagnostics Recent Developments and Future Plans
2.4 ApoCell
2.4.1 ApoCell Details
2.4.2 ApoCell Major Business
2.4.3 ApoCell Circulating Tumor Cells Product and Solutions
2.4.4 ApoCell Circulating Tumor Cells Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.4.5 ApoCell Recent Developments and Future Plans
2.5 Epic Sciences
2.5.1 Epic Sciences Details
2.5.2 Epic Sciences Major Business
2.5.3 Epic Sciences Circulating Tumor Cells Product and Solutions
2.5.4 Epic Sciences Circulating Tumor Cells Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.5.5 Epic Sciences Recent Developments and Future Plans
2.6 Greiner Bio-one GmbH
2.6.1 Greiner Bio-one GmbH Details
2.6.2 Greiner Bio-one GmbH Major Business
2.6.3 Greiner Bio-one GmbH Circulating Tumor Cells Product and Solutions
2.6.4 Greiner Bio-one GmbH Circulating Tumor Cells Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.6.5 Greiner Bio-one GmbH Recent Developments and Future Plans
2.7 Cynvenio
2.7.1 Cynvenio Details
2.7.2 Cynvenio Major Business
2.7.3 Cynvenio Circulating Tumor Cells Product and Solutions
2.7.4 Cynvenio Circulating Tumor Cells Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.7.5 Cynvenio Recent Developments and Future Plans
2.8 SurExamBio-Tech
2.8.1 SurExamBio-Tech Details
2.8.2 SurExamBio-Tech Major Business
2.8.3 SurExamBio-Tech Circulating Tumor Cells Product and Solutions
2.8.4 SurExamBio-Tech Circulating Tumor Cells Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.8.5 SurExamBio-Tech Recent Developments and Future Plans
2.9 Fluxion Biosciences
2.9.1 Fluxion Biosciences Details
2.9.2 Fluxion Biosciences Major Business
2.9.3 Fluxion Biosciences Circulating Tumor Cells Product and Solutions
2.9.4 Fluxion Biosciences Circulating Tumor Cells Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.9.5 Fluxion Biosciences Recent Developments and Future Plans
2.10 Ikonisys
2.10.1 Ikonisys Details
2.10.2 Ikonisys Major Business
2.10.3 Ikonisys Circulating Tumor Cells Product and Solutions
2.10.4 Ikonisys Circulating Tumor Cells Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.10.5 Ikonisys Recent Developments and Future Plans
2.11 Hangzhou Watson Biotech
2.11.1 Hangzhou Watson Biotech Details
2.11.2 Hangzhou Watson Biotech Major Business
2.11.3 Hangzhou Watson Biotech Circulating Tumor Cells Product and Solutions
2.11.4 Hangzhou Watson Biotech Circulating Tumor Cells Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.11.5 Hangzhou Watson Biotech Recent Developments and Future Plans
2.12 Biocept
2.12.1 Biocept Details
2.12.2 Biocept Major Business
2.12.3 Biocept Circulating Tumor Cells Product and Solutions
2.12.4 Biocept Circulating Tumor Cells Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.12.5 Biocept Recent Developments and Future Plans
2.13 CytoTrack
2.13.1 CytoTrack Details
2.13.2 CytoTrack Major Business
2.13.3 CytoTrack Circulating Tumor Cells Product and Solutions
2.13.4 CytoTrack Circulating Tumor Cells Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.13.5 CytoTrack Recent Developments and Future Plans
2.14 Guangzhou Wondfo Biotech
2.14.1 Guangzhou Wondfo Biotech Details
2.14.2 Guangzhou Wondfo Biotech Major Business
2.14.3 Guangzhou Wondfo Biotech Circulating Tumor Cells Product and Solutions
2.14.4 Guangzhou Wondfo Biotech Circulating Tumor Cells Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.14.5 Guangzhou Wondfo Biotech Recent Developments and Future Plans
2.15 Celsee
2.15.1 Celsee Details
2.15.2 Celsee Major Business
2.15.3 Celsee Circulating Tumor Cells Product and Solutions
2.15.4 Celsee Circulating Tumor Cells Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.15.5 Celsee Recent Developments and Future Plans
2.16 Clearbridge Biomedics
2.16.1 Clearbridge Biomedics Details
2.16.2 Clearbridge Biomedics Major Business
2.16.3 Clearbridge Biomedics Circulating Tumor Cells Product and Solutions
2.16.4 Clearbridge Biomedics Circulating Tumor Cells Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.16.5 Clearbridge Biomedics Recent Developments and Future Plans
2.17 ANGLE plc
2.17.1 ANGLE plc Details
2.17.2 ANGLE plc Major Business
2.17.3 ANGLE plc Circulating Tumor Cells Product and Solutions
2.17.4 ANGLE plc Circulating Tumor Cells Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.17.5 ANGLE plc Recent Developments and Future Plans
3 麻豆原创 Competition, by Players
3.1 Global Circulating Tumor Cells Revenue and Share by Players (2020-2025)
3.2 麻豆原创 Share Analysis (2024)
3.2.1 麻豆原创 Share of Circulating Tumor Cells by Company Revenue
3.2.2 Top 3 Circulating Tumor Cells Players 麻豆原创 Share in 2024
3.2.3 Top 6 Circulating Tumor Cells Players 麻豆原创 Share in 2024
3.3 Circulating Tumor Cells 麻豆原创: Overall Company Footprint Analysis
3.3.1 Circulating Tumor Cells 麻豆原创: Region Footprint
3.3.2 Circulating Tumor Cells 麻豆原创: Company Product Type Footprint
3.3.3 Circulating Tumor Cells 麻豆原创: Company Product Application Footprint
3.4 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 麻豆原创 Size Segment by Type
4.1 Global Circulating Tumor Cells Consumption Value and 麻豆原创 Share by Type (2020-2025)
4.2 Global Circulating Tumor Cells 麻豆原创 Forecast by Type (2026-2031)
5 麻豆原创 Size Segment by Application
5.1 Global Circulating Tumor Cells Consumption Value 麻豆原创 Share by Application (2020-2025)
5.2 Global Circulating Tumor Cells 麻豆原创 Forecast by Application (2026-2031)
6 North America
6.1 North America Circulating Tumor Cells Consumption Value by Type (2020-2031)
6.2 North America Circulating Tumor Cells 麻豆原创 Size by Application (2020-2031)
6.3 North America Circulating Tumor Cells 麻豆原创 Size by Country
6.3.1 North America Circulating Tumor Cells Consumption Value by Country (2020-2031)
6.3.2 United States Circulating Tumor Cells 麻豆原创 Size and Forecast (2020-2031)
6.3.3 Canada Circulating Tumor Cells 麻豆原创 Size and Forecast (2020-2031)
6.3.4 Mexico Circulating Tumor Cells 麻豆原创 Size and Forecast (2020-2031)
7 Europe
7.1 Europe Circulating Tumor Cells Consumption Value by Type (2020-2031)
7.2 Europe Circulating Tumor Cells Consumption Value by Application (2020-2031)
7.3 Europe Circulating Tumor Cells 麻豆原创 Size by Country
7.3.1 Europe Circulating Tumor Cells Consumption Value by Country (2020-2031)
7.3.2 Germany Circulating Tumor Cells 麻豆原创 Size and Forecast (2020-2031)
7.3.3 France Circulating Tumor Cells 麻豆原创 Size and Forecast (2020-2031)
7.3.4 United Kingdom Circulating Tumor Cells 麻豆原创 Size and Forecast (2020-2031)
7.3.5 Russia Circulating Tumor Cells 麻豆原创 Size and Forecast (2020-2031)
7.3.6 Italy Circulating Tumor Cells 麻豆原创 Size and Forecast (2020-2031)
8 Asia-Pacific
8.1 Asia-Pacific Circulating Tumor Cells Consumption Value by Type (2020-2031)
8.2 Asia-Pacific Circulating Tumor Cells Consumption Value by Application (2020-2031)
8.3 Asia-Pacific Circulating Tumor Cells 麻豆原创 Size by Region
8.3.1 Asia-Pacific Circulating Tumor Cells Consumption Value by Region (2020-2031)
8.3.2 China Circulating Tumor Cells 麻豆原创 Size and Forecast (2020-2031)
8.3.3 Japan Circulating Tumor Cells 麻豆原创 Size and Forecast (2020-2031)
8.3.4 South Korea Circulating Tumor Cells 麻豆原创 Size and Forecast (2020-2031)
8.3.5 India Circulating Tumor Cells 麻豆原创 Size and Forecast (2020-2031)
8.3.6 Southeast Asia Circulating Tumor Cells 麻豆原创 Size and Forecast (2020-2031)
8.3.7 Australia Circulating Tumor Cells 麻豆原创 Size and Forecast (2020-2031)
9 South America
9.1 South America Circulating Tumor Cells Consumption Value by Type (2020-2031)
9.2 South America Circulating Tumor Cells Consumption Value by Application (2020-2031)
9.3 South America Circulating Tumor Cells 麻豆原创 Size by Country
9.3.1 South America Circulating Tumor Cells Consumption Value by Country (2020-2031)
9.3.2 Brazil Circulating Tumor Cells 麻豆原创 Size and Forecast (2020-2031)
9.3.3 Argentina Circulating Tumor Cells 麻豆原创 Size and Forecast (2020-2031)
10 Middle East & Africa
10.1 Middle East & Africa Circulating Tumor Cells Consumption Value by Type (2020-2031)
10.2 Middle East & Africa Circulating Tumor Cells Consumption Value by Application (2020-2031)
10.3 Middle East & Africa Circulating Tumor Cells 麻豆原创 Size by Country
10.3.1 Middle East & Africa Circulating Tumor Cells Consumption Value by Country (2020-2031)
10.3.2 Turkey Circulating Tumor Cells 麻豆原创 Size and Forecast (2020-2031)
10.3.3 Saudi Arabia Circulating Tumor Cells 麻豆原创 Size and Forecast (2020-2031)
10.3.4 UAE Circulating Tumor Cells 麻豆原创 Size and Forecast (2020-2031)
11 麻豆原创 Dynamics
11.1 Circulating Tumor Cells 麻豆原创 Drivers
11.2 Circulating Tumor Cells 麻豆原创 Restraints
11.3 Circulating Tumor Cells Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 Industry Chain Analysis
12.1 Circulating Tumor Cells Industry Chain
12.2 Circulating Tumor Cells Upstream Analysis
12.3 Circulating Tumor Cells Midstream Analysis
12.4 Circulating Tumor Cells Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Menarini-Silicon Biosystems
Qiagen (Adnagen)
Advanced Cell Diagnostics
ApoCell
Epic Sciences
Greiner Bio-one GmbH
Cynvenio
SurExamBio-Tech
Fluxion Biosciences
Ikonisys
Hangzhou Watson Biotech
Biocept
CytoTrack
Guangzhou Wondfo Biotech
Celsee
Clearbridge Biomedics
ANGLE plc
听
听
*If Applicable.
